skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Improvement of the noradrenergic symptom cluster following treatment with milnacipran

Short Report

(1301) Views  (326) Full article downloads

Authors: Kasper S, Meshkat D, Kutzelnigg A

Published Date May 2011 Volume 2011:7(Supplement 1) Pages 21 - 27
DOI: http://dx.doi.org/10.2147/NDT.S19615

Siegfried Kasper, Diana Meshkat, Alexandra Kutzelnigg
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

Abstract: Depression has a major impact on social functioning. Decreased concentration, mental and physical slowing, loss of energy, lassitude, tiredness, and reduced self-care are all symptoms related to reduced noradrenergic activity. Depressed mood; loss of interest or pleasure; sleep disturbances; and feelings of worthlessness, pessimism, and anxiety are related to reduced activity of both serotonergic and noradrenergic neurotransmission. The importance of noradrenergic neurotransmission in social functioning is supported by studies with the specific norepinephrine reuptake inhibitor reboxetine. In healthy volunteers, reboxetine increases cooperative social behavior and social drive. A placebo-controlled study in depressed patients comparing reboxetine with the selective serotonin reuptake inhibitor (SSRI) fluoxetine showed significantly greater improvement in social adaptation with reboxetine. Two recent studies have examined the effect of the serotonin and norepinephrine reuptake inhibitor milnacipran on social adaptation. A study in depressed patients found that at the end of 8 weeks of treatment with milnacipran, 42.2% patients were in remission on the Social Adaptation Self-evaluation Scale (SASS). Another study in depressed workers or homemakers found that mean depression scores were significantly reduced after 2 weeks, whereas the SASS scores were significantly improved after 4 weeks. A preliminary study comparing depressed patients treated with milnacipran or the SSRI paroxetine showed that milnacipran treatment resulted in a greater number of patients in social remission. The available data thus suggest that milnacipran may improve social functioning, with a possibly greater effect than the SSRI paroxetine. These preliminary data suggest further evaluation of social dysfunction and its treatment outcome in future trials of milnacipran.

Keywords: social functioning, Social Adaptation Self-evaluation Scale (SASS), depression, noradrenergic neurotransmission, serotonin and norepinephrine reuptake inhibitors (SNRIs), milnacipran




 

Other articles by Dr Mike Briley

Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study
Antidepressant therapy with milnacipran and venlafaxine
Choking risk among psychiatric inpatients
Editorial Foreword - Milnacipran: recent findings in depression
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
Milnacipran: a unique antidepressant?
Milnacipran: recent findings in depression
Noradrenergic symptom cluster in depression
Psychiatric diagnoses in patients with burning mouth syndrome and atypical odontalgia referred from psychiatric to dental facilities
Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series
Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran
The importance of norepinephrine in depression
The increasing burden of depression
The noradrenergic symptom cluster: clinical expression and neuropharmacology
Treatment of patients with comorbid depression and diabetes with metformin and milnacipran


Readers of this article also read:

Adenylyl cyclase-cyclicAMP signaling in mood disorders: Role of the crucial phosphorylating enzyme protein kinase A
Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues
Milnacipran: recent findings in depression
Editorial Foreword - Milnacipran: recent findings in depression
Antidepressant therapy with milnacipran and venlafaxine
Milnacipran: a unique antidepressant?
Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series
Neuroimmune endocrine effects of antidepressants
Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use